STOCK TITAN

Insider Sean McAuliffe plans 914-share Taysha (NASDAQ: TSHA) stock sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Taysha Gene Therapies insider Sean McAuliffe has filed to sell additional company stock. The notice covers 914 shares of common stock, to be sold through Maxim Group LLC on or around February 4, 2026 on Nasdaq, with an aggregate market value of $4,314.08. The filing states that 273,919,373 shares of common stock were outstanding.

The 914 shares come from a restricted stock unit award acquired on February 3, 2026, which vested and was settled in stock as compensation for continued employment. In the past three months, McAuliffe also sold 36,071 shares for $171,337.25 and 10,894 shares for $50,221.34.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the latest Form 144 filing for TSHA disclose?

The filing shows Sean McAuliffe plans to sell 914 shares of Taysha Gene Therapies common stock. The planned sale, via Maxim Group LLC on Nasdaq, has an aggregate market value of $4,314.08 based on the price used in the notice.

Who is selling Taysha Gene Therapies (TSHA) shares in this notice?

The seller is Sean McAuliffe, listed with a care-of address at Taysha Gene Therapies in Dallas, Texas. He is the person for whose account the securities are to be sold under this Rule 144 notice.

How many TSHA shares are covered by this planned Rule 144 sale?

The notice covers 914 shares of Taysha Gene Therapies common stock. These shares are to be sold through broker Maxim Group LLC on or about February 4, 2026, as stated in the filing’s securities information table.

How were the 914 TSHA shares in this filing acquired?

The 914 shares were acquired on February 3, 2026 via a restricted stock unit (RSU) award. The filing explains the RSU vested and was settled in stock, with consideration being McAuliffe’s continued service as an employee of the issuer.

What prior TSHA stock sales by Sean McAuliffe are disclosed?

The document lists two prior sales in the past three months: 36,071 shares of common stock sold on January 23, 2026 for $171,337.25, and 10,894 shares sold on January 26, 2026 for $50,221.34 in gross proceeds.

How many Taysha Gene Therapies shares are outstanding in this filing?

The filing reports that 273,919,373 shares of Taysha Gene Therapies common stock were outstanding. This figure provides context for the relative size of the 914-share sale described in the notice.
Taysha Gene Therapies, Inc.

NASDAQ:TSHA

TSHA Rankings

TSHA Latest News

TSHA Latest SEC Filings

TSHA Stock Data

1.21B
242.28M
11.15%
94.76%
14.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
DALLAS